US 12,221,443 B2
Crystalline forms of diazabicyclooctane derivative and production process thereof
Takao Abe, Kanagawa (JP); Takeshi Furuuchi, Kanagawa (JP); Yoshiaki Sakamaki, Kanagawa (JP); Nakako Mitsuhashi, Kanagawa (JP); and Yumiko Saito, Kanagawa (JP)
Assigned to MEIJI SEIKA PHARMA CO., LTD., Tokyo (JP)
Filed by MEIJI SEIKA PHARMA CO., LTD., Tokyo (JP)
Filed on Jul. 7, 2022, as Appl. No. 17/859,015.
Application 17/859,015 is a division of application No. 16/793,843, filed on Feb. 18, 2020, granted, now 11,414,417.
Application 16/793,843 is a continuation of application No. 16/148,774, filed on Oct. 1, 2018, granted, now 10,604,522, issued on Mar. 31, 2020.
Application 16/148,774 is a continuation of application No. 15/027,956, granted, now 10,131,665, issued on Nov. 20, 2018, previously published as PCT/JP2014/076875, filed on Oct. 8, 2014.
Claims priority of application No. 2013-211242 (JP), filed on Oct. 8, 2013.
Prior Publication US 2022/0348578 A1, Nov. 3, 2022
Int. Cl. C07D 471/08 (2006.01); A61K 31/439 (2006.01); A61K 45/06 (2006.01)
CPC C07D 471/08 (2013.01) [A61K 31/439 (2013.01); A61K 45/06 (2013.01); C07B 2200/13 (2013.01)] 7 Claims
OG exemplary drawing
 
1. A crystalline form II of a compound represented by Formula (VII-1):

OG Complex Work Unit Chemistry
having characteristic peaks appearing at lattice spacing (d) of 9.46, 5.62, 5.23, 5.10, 5.00, 4.91, 4.67, 4.45, 4.29, 3.96, 3.78, 3.71, 3.52, 3.24, 3.18, 3.10, 3.02, 2.88, 2.81, 2.77, 2.67, 2.50 and 2.45 Å in the powder X-ray diffraction pattern.